International Stem Cell Corp Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the …

CARLSBAD, CA--(Marketwire - Oct 9, 2012) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, congratulates Sir John Gurdon and Dr. Shinya Yamanaka on the recently announced Nobel Prize in Physiology or Medicine for discovering cellular reprogramming to create pluripotent stem cells.These discoveries lead to the development of induced pluripotent stem cells (iPS) which is now a major area of research.However, currently cellular reprogramming is accomplished by inserting genetic material, via a virus or otherwise, which raises serious safety concerns when developing treatments.ISCO has developed a technology that potentially allows for the creation of a new generation of iPS cells without these safety concerns.Unlike methods requiring the use of viruses or DNA constructs that may integrate into the genome, ISCO's new method utilizes only proteins which are naturally eliminated once they have served their purpose.

Dr. Ruslan Semechkin, Vice President and head of ISCO's Research and Development comments, "Overall, our new technology represents a level of control that is much finer than the multiple infections necessary for viral-based systems which cannot be turned off and where the dosage level cannot be modulated.Moreover, ISCO's method can be used not only to reprogram somatic cells to become stem cells, but also transform stem cells into somatic cells.This technology provides an alternative to the existing cellular reprogramming methods and represents an enormous opportunity for ISCO to become a leader in the iPS field."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products.ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos.ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments, the potential uses of our technologies and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" or "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Go here to read the rest:
International Stem Cell Corp Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the ...